Does the media favor SNDX or RYTM?

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for Rhythm Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat Rhythm Pharmaceuticals' score of 0.83 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rhythm Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTCT or SNDX?

In the previous week, PTC Therapeutics had 7 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 13 mentions for PTC Therapeutics and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat PTC Therapeutics' score of 0.69 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to SNDX or MIRM?

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat Mirum Pharmaceuticals' score of 0.71 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Mirum Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CNTA or SNDX?

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for Centessa Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat Centessa Pharmaceuticals' score of 0.72 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer RGC or SNDX?

Syndax Pharmaceuticals has a consensus target price of $42.55, suggesting a potential upside of 116.96%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Syndax Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.92

Which has better earnings & valuation, RGC or SNDX?

Regencell Bioscience has higher earnings, but lower revenue than Syndax Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Syndax Pharmaceuticals $172.35M 10.08 -$285.42M -$2.79 N/A

Does the media refer more to RGC or SNDX?

In the previous week, Regencell Bioscience had 16 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 22 mentions for Regencell Bioscience and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat Regencell Bioscience's score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Syndax Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Syndax Pharmaceuticals (SNDX) Competitors

$19.61 +0.29 (+1.50%)

As of 06/23/2026 04:00 PM Eastern

Compare

SNDX vs. RYTM, PTCT, MIRM, CNTA, and RGC

Should you buy Syndax Pharmaceuticals stock or one of its competitors? MarketBeat compares Syndax Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Syndax Pharmaceuticals include Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Mirum Pharmaceuticals (MIRM), Centessa Pharmaceuticals (CNTA), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry.

How does Syndax Pharmaceuticals compare to Rhythm Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Syndax Pharmaceuticals presently has a consensus price target of $42.55, indicating a potential upside of 116.96%. Rhythm Pharmaceuticals has a consensus price target of $133.13, indicating a potential upside of 25.36%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Syndax Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Syndax Pharmaceuticals' net margin of -111.88%. Rhythm Pharmaceuticals' return on equity of -203.25% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Syndax Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market.

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for Rhythm Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat Rhythm Pharmaceuticals' score of 0.83 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rhythm Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.08	-$285.42M	-$2.79	N/A
Rhythm Pharmaceuticals	$189.76M	38.35	-$196.54M	-$3.13	N/A

Summary

Rhythm Pharmaceuticals beats Syndax Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, PTC Therapeutics had 7 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 13 mentions for PTC Therapeutics and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat PTC Therapeutics' score of 0.69 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

PTC Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

PTC Therapeutics currently has a consensus target price of $91.36, indicating a potential upside of 11.23%. Syndax Pharmaceuticals has a consensus target price of $42.55, indicating a potential upside of 116.96%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

PTC Therapeutics has a net margin of -22.58% compared to Syndax Pharmaceuticals' net margin of -111.88%. Syndax Pharmaceuticals' return on equity of -256.65% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

PTC Therapeutics has higher revenue and earnings than Syndax Pharmaceuticals. PTC Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.94	$682.64M	-$2.33	N/A
Syndax Pharmaceuticals	$172.35M	10.08	-$285.42M	-$2.79	N/A

Summary

PTC Therapeutics and Syndax Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Syndax Pharmaceuticals presently has a consensus target price of $42.55, suggesting a potential upside of 116.96%. Mirum Pharmaceuticals has a consensus target price of $139.80, suggesting a potential upside of 25.73%. Given Syndax Pharmaceuticals' higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat Mirum Pharmaceuticals' score of 0.71 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Mirum Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals has a net margin of -111.88% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Mirum Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.08	-$285.42M	-$2.79	N/A
Mirum Pharmaceuticals	$521.31M	13.01	-$23.36M	-$13.61	N/A

Syndax Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Centessa Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Centessa Pharmaceuticals presently has a consensus price target of $41.33, indicating a potential upside of 2.06%. Syndax Pharmaceuticals has a consensus price target of $42.55, indicating a potential upside of 116.96%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for Centessa Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat Centessa Pharmaceuticals' score of 0.72 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Centessa Pharmaceuticals has higher earnings, but lower revenue than Syndax Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Syndax Pharmaceuticals	$172.35M	10.08	-$285.42M	-$2.79	N/A

Centessa Pharmaceuticals has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Centessa Pharmaceuticals' return on equity of -60.37% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Summary

Syndax Pharmaceuticals beats Centessa Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Regencell Bioscience has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Regencell Bioscience's return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Regencell Bioscience has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

0.1% of Regencell Bioscience shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Regencell Bioscience had 16 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 22 mentions for Regencell Bioscience and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat Regencell Bioscience's score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Regencell Bioscience has higher earnings, but lower revenue than Syndax Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Syndax Pharmaceuticals	$172.35M	10.08	-$285.42M	-$2.79	N/A

Syndax Pharmaceuticals has a consensus target price of $42.55, suggesting a potential upside of 116.96%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Regencell Bioscience and Syndax Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Syndax Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNDX vs. The Competition

Export

Metric	Syndax Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.71B	$3.45B	$6.44B	$12.38B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-7.03	19.75	24.66	23.99
Price / Sales	10.08	330.63	528.55	106.76
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	26.50	8.29	10.83	6.50
Net Income	-$285.42M	$23.85M	$3.56B	$336.88M
7 Day Performance	2.99%	2.87%	0.93%	-0.16%
1 Month Performance	-1.65%	2.19%	0.36%	0.76%
1 Year Performance	112.69%	55.48%	29.66%	28.49%

Syndax Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNDX Syndax Pharmaceuticals	3.6454 of 5 stars	$19.61 +1.5%	$42.55 +117.0%	+113.4%	$1.71B	$172.35M	N/A	110
RYTM Rhythm Pharmaceuticals	3.1609 of 5 stars	$96.79 flat	$133.13 +37.5%	+70.9%	$6.63B	$189.76M	N/A	140	High Trading Volume
PTCT PTC Therapeutics	2.5463 of 5 stars	$78.98 flat	$91.36 +15.7%	+65.6%	$6.55B	$827.11M	N/A	1,410	Insider Trade
MIRM Mirum Pharmaceuticals	3.9534 of 5 stars	$107.13 flat	$139.80 +30.5%	+121.1%	$6.53B	$521.31M	N/A	140	Gap Down High Trading Volume
CNTA Centessa Pharmaceuticals	1.4471 of 5 stars	$40.02 flat	$41.33 +3.3%	+211.5%	$6.19B	$15M	N/A	200	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNDX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. RYTM, PTCT, MIRM, CNTA, and RGC

How does Syndax Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Syndax Pharmaceuticals compare to PTC Therapeutics?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Syndax Pharmaceuticals compare to Centessa Pharmaceuticals?

Summary

How does Syndax Pharmaceuticals compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. RYTM, PTCT, MIRM, CNTA, and RGC

How does Syndax Pharmaceuticals compare to Rhythm Pharmaceuticals?

Do analysts rate SNDX or RYTM?

Is SNDX or RYTM more profitable?

Which has more risk & volatility, SNDX or RYTM?

Does the media favor SNDX or RYTM?

Which has stronger earnings & valuation, SNDX or RYTM?

Summary

How does Syndax Pharmaceuticals compare to PTC Therapeutics?

Does the media refer more to PTCT or SNDX?

Which has more volatility and risk, PTCT or SNDX?

Do analysts prefer PTCT or SNDX?

Is PTCT or SNDX more profitable?

Which has preferable valuation & earnings, PTCT or SNDX?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Do analysts rate SNDX or MIRM?

Does the media refer more to SNDX or MIRM?

Is SNDX or MIRM more profitable?

Which has better earnings & valuation, SNDX or MIRM?

Which has more volatility and risk, SNDX or MIRM?

Summary

How does Syndax Pharmaceuticals compare to Centessa Pharmaceuticals?

Do insiders & institutionals have more ownership in CNTA or SNDX?

Which has more risk and volatility, CNTA or SNDX?

Do analysts rate CNTA or SNDX?

Does the media favor CNTA or SNDX?

Which has preferable earnings & valuation, CNTA or SNDX?

Is CNTA or SNDX more profitable?

Summary

How does Syndax Pharmaceuticals compare to Regencell Bioscience?

Is RGC or SNDX more profitable?

Which has more volatility & risk, RGC or SNDX?

Do institutionals and insiders hold more shares of RGC or SNDX?

Does the media refer more to RGC or SNDX?

Which has better earnings & valuation, RGC or SNDX?

Do analysts prefer RGC or SNDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools